Journal
BLOOD
Volume 114, Issue 25, Pages 5201-5205Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-06-223982
Keywords
-
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan [17590998, 18591063, 19591114]
- Japan Leukemia Research Fund
- Grants-in-Aid for Scientific Research [18591063, 19591114, 17590998] Funding Source: KAKEN
Ask authors/readers for more resources
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lineages. Some patients exhibit leukemic transformation (LT) by unknown mechanisms, and chemotherapy may increase the risk of LT. To clarify the molecular mechanisms of LT, gene alterations involved in LT from patients in the chronic phase (CP) of MPNs were identified. Among 18 patients who progressed to leukemia, AML1/RUNX1 mutations were detected in 5 patients at the LT but in none at the CP. To investigate the leukemogenic effect of AML1/RUNX1 mutants, the AML1D171N mutant was transduced into CD34(+) cells from patients in the CP of MPNs. The D171N transduction resulted in proliferation of immature myeloid cells, enhanced self-renewal capacity, and proliferation of primitive progenitors. Taken together, these results indicate that AML1/RUNX1 point mutations may have a leukemogenic potential in MPN stem cells, and they may promote leukemic transformation in MPN. (Blood. 2009; 114: 5201-5205)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available